

Breast Cancer Pathways: Neoadjuvant and Adjuvant

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: Neoadjuvant/Pre-Op Adjuvant/Post-Op

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

Estrogen Receptor (ER): Negative Positive

OncotypeDx: Low* Intermediate

Progesterone Receptor (PR): Negative Positive

High Not Done/Reported

HER2 status by FISH/CISH: Negative Positive Equivocal

Include ovarian suppression (pre-menopause only):

or by IHC: 0 1+ 2+ 3+

Yes No Unknown

Neoadjuvant and Adjuvant Therapy | HER2 Negative

ddAC → weekly T: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel

TC: docetaxel (Taxotere) and cyclophosphamide

Neoadjuvant and Adjuvant Therapy | HER2 Positive

AC → TH: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel and trastuzumab*

TCH: docetaxel (Taxotere), carboplatin, and trastuzumab*

Neoadjuvant Therapy | HER2 Positive | Hormone Receptor (ER/PR) Negative

TCH+P: docetaxel (Taxotere), carboplatin, trastuzumab, and pertuzumab (Perjeta)

Adjuvant Therapy | HER2 Positive

TH: paclitaxel and trastuzumab (**Pathway for stage I, HER2 positive breast cancer only**)*

Adjuvant Therapy | HER2 Negative | Hormone Receptor (ER/PR) Negative | Residual Disease following Neoadjuvant Therapy

Capecitabine

Adjuvant Therapy | HER2 Positive | Residual Disease following Neoadjuvant Therapy

Ado-trastuzumab emtansine (Kadcyla)

* Administration of trastuzumab is limited to 1 year (maximum 18 cycles)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 2/25/2020 | Effective date: 5/4/2020

Appropriate.Safe.Affordable

© 2020 AIM Specialty Health
9001-0720